share_log

iBio Inc | UPLOAD: Others

iBio Inc | UPLOAD: Others

iBio Inc | UPLOAD:其他
美股sec公告 ·  04/22 13:12
Moomoo AI 已提取核心信息
On April 22, 2024, iBio Inc, a biotechnology company, received communication from the Division of Corporation Finance Office of Life Sciences at the United States Securities and Exchange Commission (SEC). The SEC informed iBio Inc's Chief Financial Officer, Felipe Duran, that its Registration Statement on Form S-3, filed on April 16, 2024, with the file number 333-278729, will not be reviewed by the staff. The SEC's letter reminded the company of its responsibility for the accuracy and adequacy of disclosures in the registration statement. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. For further inquiries, the SEC provided contact information for Jimmy McNamara. The notice concluded with a reminder of the company's responsibility for its disclosures, irrespective of the SEC's review process.
On April 22, 2024, iBio Inc, a biotechnology company, received communication from the Division of Corporation Finance Office of Life Sciences at the United States Securities and Exchange Commission (SEC). The SEC informed iBio Inc's Chief Financial Officer, Felipe Duran, that its Registration Statement on Form S-3, filed on April 16, 2024, with the file number 333-278729, will not be reviewed by the staff. The SEC's letter reminded the company of its responsibility for the accuracy and adequacy of disclosures in the registration statement. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. For further inquiries, the SEC provided contact information for Jimmy McNamara. The notice concluded with a reminder of the company's responsibility for its disclosures, irrespective of the SEC's review process.
2024年4月22日,生物技术公司iBio Inc收到了美国证券交易委员会(SEC)公司财务部生命科学办公室的来文。美国证券交易委员会告知iBio Inc的首席财务官费利佩·杜兰,其于2024年4月16日提交的文件编号为333-278729的S-3表格注册声明将不由工作人员审查。美国证券交易委员会的信提醒该公司对注册声明中披露的准确性和充分性负责。美国证券交易委员会还引用了与加快注册程序的请求有关的第460和461条。为了进一步调查,美国证券交易委员会提供了吉米·麦克纳马拉的联系信息。该通知最后提醒我们,无论美国证券交易委员会的审查程序如何,该公司都应对其披露负责。
2024年4月22日,生物技术公司iBio Inc收到了美国证券交易委员会(SEC)公司财务部生命科学办公室的来文。美国证券交易委员会告知iBio Inc的首席财务官费利佩·杜兰,其于2024年4月16日提交的文件编号为333-278729的S-3表格注册声明将不由工作人员审查。美国证券交易委员会的信提醒该公司对注册声明中披露的准确性和充分性负责。美国证券交易委员会还引用了与加快注册程序的请求有关的第460和461条。为了进一步调查,美国证券交易委员会提供了吉米·麦克纳马拉的联系信息。该通知最后提醒我们,无论美国证券交易委员会的审查程序如何,该公司都应对其披露负责。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息